公开(公告)号：US12122824B2

公开(公告)日：2024-10-22

申请号：US17320490

申请日：2021-05-14

申请人： Janssen Biotech, Inc.

发明人： Diane D. Harrison ,  Elizabeth C. Hsia ,  Lee-Lian Kim ,  Kim Hung Lo

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K31/519 ,  A61P19/02 ,  C07K16/24 ,  A61K39/00

CPC分类号： C07K16/241 ,  A61K9/0019 ,  A61K31/519 ,  A61K39/3955 ,  A61P19/02 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76

摘要： The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).

公开(公告)号：US12109190B2

公开(公告)日：2024-10-08

申请号：US17822027

申请日：2022-08-24

申请人： Amazentis SA

发明人： Anurag Singh ,  Davide D'Amico ,  Penelope Andreux ,  William Blanco-Bose ,  Christopher L. Rinsch

IPC分类号： A61K31/37 ,  A61K31/335 ,  A61K39/00 ,  A61K39/145 ,  A61K39/39 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P31/16 ,  A61P35/00 ,  C07D311/80

CPC分类号： A61K31/37 ,  A61K31/335 ,  A61K39/0011 ,  A61K39/145 ,  A61K39/39 ,  A61P31/16 ,  A61K2039/55 ,  A61K2039/55511 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P35/00 ,  C07D311/80 ,  A61K2300/00 ,  A61K31/366

摘要： Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.

公开(公告)号：US20240316042A1

公开(公告)日：2024-09-26

申请号：US18612955

申请日：2024-03-21

申请人： AbbVie Inc.

发明人： Mohamed-Eslam F. Mohamed ,  Cheng Thiam Tan ,  Henrique D. Teixeira ,  Alvina D. Chu

IPC分类号： A61K31/4985 ,  A61P17/00 ,  A61P19/02

CPC分类号： A61K31/4985 ,  A61P17/00 ,  A61P19/02

摘要： The present disclosure is directed to methods for treating disease in pediatric patients with the JAK1 selective inhibitor upadacitinib. The diseases and disorders include idiopathic arthritis (pcJIA), systemic juvenile idiopathic arthritis (SJIA), juvenile psoriatic arthritis (JPsA), atopic dermatitis (AD), juvenile ankylosing spondylitis (JAS), juvenile non-radiographic spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS), systemic lupus erythematosus (SLE), ulcerative colitis (UC), and Crohn's disease (CD). The treatment methods generally comprise administering to a pediatric patient a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

公开(公告)号：US12091661B2

公开(公告)日：2024-09-17

申请号：US17714272

申请日：2022-04-06

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2320/31 ,  C12N2320/51 ,  C12N2320/53 ,  Y02A50/30 ,  C12N2310/321 ,  C12N2310/3521

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US12091465B2

公开(公告)日：2024-09-17

申请号：US16637357

申请日：2018-08-14

申请人： Seoul National University R&DB Foundation

发明人： Doo Hyun Chung ,  Eugene C. Yi ,  Dongjin Jeong ,  Min Jueng Kang ,  Donghyun Kim

IPC分类号： C07K14/705 ,  A61P19/02 ,  C07K14/71 ,  C07K16/28 ,  C12N15/113 ,  G01N33/68 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61P19/02 ,  C07K14/70578 ,  C07K14/70596 ,  C12N15/113 ,  C12N15/1138 ,  G01N33/6872 ,  A61K2039/505 ,  C12N2310/11 ,  C12N2310/14 ,  G01N2333/70578

摘要： The present invention relates to a composition for preventing or treating diseases caused by overexpression of chemokine CX3CL1 (fractalkine) comprising a death receptor 5 (DR5) inhibitor as an active ingredient, a method for preventing or treating diseases caused by overexpression of chemokine CX3CL1 comprising administering a DR5 expression or activity inhibitor to a patient in need of prevention or treatment of diseases caused by overexpression of chemokine CX3CL1 in a therapeutically effective amount, and a use for prevention or treatment of diseases caused by overexpression of chemokine CX3CL1 of a DR5 expression or activity inhibitor.

公开(公告)号：US20240285711A1

公开(公告)日：2024-08-29

申请号：US18576255

申请日：2022-07-01

申请人： Altergon S.A.

发明人： Andrea Maria Giori ,  Andrea Alimonti

IPC分类号： A61K36/537 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00

CPC分类号： A61K36/537 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61K2236/333 ,  A61K2236/39 ,  A61K2236/51

摘要： The present invention relates to the use of Salvia haenkei extract as an active agent in the treatment of musculoskeletal disorders, being able to offer a significant contribution in slowing, relieving, reducing and/or preventing alterations and damages of the musculoskeletal tissues. Furthermore, the present invention also relates to a pharmaceutical composition comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of musculoskeletal disorders.

公开(公告)号：US20240285583A1

公开(公告)日：2024-08-29

申请号：US18569571

申请日：2022-06-15

申请人： LG CHEM, LTD.

发明人： Jieun LEE ,  Heemin GWAK ,  Seong Hye SHIN ,  Ji Young MIN ,  Min Hee KIM ,  Junyu KIM ,  Jung Youn SEO ,  June Sik MUNE

IPC分类号： A61K31/4155 ,  A61K9/00 ,  A61K45/06 ,  A61P19/02

CPC分类号： A61K31/4155 ,  A61K9/0053 ,  A61K45/06 ,  A61P19/02

摘要： The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or inhibiting a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.

公开(公告)号：US20240279326A1

公开(公告)日：2024-08-22

申请号：US18594234

申请日：2024-03-04

申请人： Pfizer Inc. ,  The Regents of the University of California

发明人： Rachel Groth ,  William Brian Snyder ,  Xianjun Cao ,  Robert J. Dunn ,  Joseph Dal Porto ,  Michael Karin

IPC分类号： C07K16/24 ,  A61K39/00 ,  A61P19/02 ,  A61P37/06 ,  C07K16/28 ,  C07K16/40 ,  C12N15/62

CPC分类号： C07K16/24 ,  A61P19/02 ,  A61P37/06 ,  C07K16/2866 ,  C07K16/40 ,  C12N15/62 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

公开(公告)号：US12065441B2

公开(公告)日：2024-08-20

申请号：US16972605

申请日：2019-06-05

申请人： GENGLE THERAPEUTICS, INC.

发明人： Jianming Yin

IPC分类号： C07D487/04 ,  A61P1/00 ,  A61P7/00 ,  A61P17/00 ,  A61P17/04 ,  A61P19/02 ,  A61P19/08 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  C07D471/04

CPC分类号： C07D487/04 ,  A61P1/00 ,  A61P7/00 ,  A61P17/00 ,  A61P17/04 ,  A61P19/02 ,  A61P19/08 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  C07D471/04

摘要： Disclosed is a pyrazolopyrimidine derivative having a structure represented by general formula (I), a pharmaceutically acceptable salt, hydrate and metabolite formed by metabolism in any form thereof, and use in preparing drugs for preventing and/or treating indications associated with JAK kinase function, and a pharmaceutical composition prepared therefrom for preventing and/or treating indications associated with JAK kinase function. The present disclosure is a selective JAK kinase inhibitor, which has a pharmaceutical therapeutic effect on immunity and inflammatory responses by acting on JAK kinase.

公开(公告)号：US20240239913A1

公开(公告)日：2024-07-18

申请号：US18411242

申请日：2024-01-12

申请人： The United States Government As Represented By The Department Of Veterans Affairs ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  OKLAHOMA MEDICAL RESEARCH FOUNDATION

发明人： CARLA R. SCANZELLO ,  TIMOTHY GRIFFIN

IPC分类号： C07K16/28 ,  A61P19/02 ,  C07K14/745 ,  C12N9/12 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61P19/02 ,  C07K14/7455 ,  C12N9/12 ,  A61K38/00 ,  A61K2039/505 ,  C12Y207/12002

摘要： Disclosed herein are methods of treating or preventing the development of osteoarthritis after a joint injury by administering a CD14 inhibitor capable of neutralizing or blocking CD14, inhibiting CD14 function, inhibiting CD14 production, or a combination thereof. Also disclosed herein are methods of reducing or ameliorating one or more symptoms of osteoarthritis, reducing inflammation, reducing cartilage degradation, or treating or preventing subchondral bone sclerosis in a subject.